Shares of Aflac rocketed 8.07% to $131.79 on August 11, defying a quarter where the supplemental insurance giant narrowly missed its profit target, raising a pointed question: are investors betting on the company's financial engineering rather than its top-line growth? Aflac's Stock Pops 8% After a Quarter It Barely Won — Can Buybacks Keep Doing the Heavy Lifting?
Shares surged 8.07% to $131.79 as investors digested a second-quarter earnings report that, on paper, was mediocre — but underneath revealed a company aggressively shrinking itself richer through one of the insurance industry's most relentless share-buyback programs.
• A Slight Earnings Miss Masked by Massive Cash Returns
Aflac posted adjusted earnings of $1.75 per share , narrowly missing the $1.78 consensus. Revenue came in at $4.12 billion with net income of $825 million, up 37.7% year over year. The real headline: the company returned $1.3 billion to shareholders in Q2 alone — $983 million in stock buybacks and $309 million in dividends. That buyback pace is shrinking the share count fast enough to boost per-share profits even when total earnings decline. Adjusted earnings actually fell 7.7% to $883 million , yet diluted EPS still rose 46.8% year over year thanks to fewer shares outstanding and investment gains.
• Piper Sandler's Bullish Call Towers Over a Skeptical Street
Piper Sandler analyst Paul Newsome raised his price target to $138 from $130 and kept an Overweight rating. That is now the highest target among 10 tracked analysts, where the average sits at just $117.44 — well below today's price. Jefferies simultaneously lifted its target to only $112 with a Hold rating, and Barclays holds an Underweight at just $98. The split signals the stock has already priced in optimism that most of Wall Street doesn't share.
• Japan Is Steady, but the U.S. Business Is Slowing
Aflac Japan's first-half sales rose 7% year over year , and pretax profit margins in Japan improved to 34.3% from 32.0%. The U.S. side is wobblier: net earned premium growth for 2026 is now expected to fall below the prior 3%–6% guidance range.
The U.S. benefit ratio — what Aflac pays out in claims relative to premiums collected — climbed 220 basis points to 49.5% , pressured by higher disability claims.
• A $4.8 Billion Portfolio Shuffle Bets on Higher Yields Ahead
Aflac repositioned $4.8 billion of investments, a move expected to raise annual net investment income by more than $50 million.
A weaker yen shaved $0.05 off Q2 adjusted EPS , a recurring headwind for a company earning roughly two-thirds of revenue in Japan.
At $131.79, Aflac now trades above every analyst target except Piper Sandler's. The question for investors: how long can buyback-fueled EPS growth sustain a stock that's outrunning its own earnings?